시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 레이노병 치료 시장 보고서(2025년)
Raynauds Disease Treatment Global Market Report 2025
상품코드 : 1769731
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,312,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,124,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,936,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

레이노병 치료 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 비율의 상승, 세계의 헬스 케어 시스템의 개선 등을 들 수 있습니다. 예측 기간 중에 예상되는 주목할 만한 동향에는 조기 발견과 질병 추적을 위한 AI의 이용, 디지털 열 진단 툴의 혁신, 표적 생물학적 치료의 진보, 유전자 편집과 세포 치료의 새로운 진보, 디지털 헬스와 원격 의료 솔루션의 광범위한 도입 등 입니다.

자가면역 질환의 유병률 증가는 레이노병 치료 시장의 확대를 촉진할 것으로 예상되고 있습니다. 면역계의 훈련을 제한하는 도시화와 위생화된 생활 환경, 식생활의 혼란, 스트레스, 환경 오염물질 등의 현대적인 라이프 스타일 요소 등의 요인에 기인하고 있습니다. 혈류 제한으로 인한 합병증을 예방함으로써 자가면역 증상을 관리하는 데 도움이 됩니다. 2024년 6월, 호주 보건 복지 연구소(Australian Institute of Health and Welfare)의 보고서에 따르면, 2021-22년 호주에서는 류마티스 관절염으로 인한 입원 건수가 10,000건을 기록했습니다. 이는 전년도 8,000건에서 25% 증가한 수치이며, 인구 10만 명당 39건의 입원에 해당합니다.

건강 관리 지출 증가는 레이노 병 치료 시장의 성장에 기여할 것으로 예측됩니다. 전 세계 인구가 고령화됨에 따라 의료 서비스, 장기 요양, 그리고 노화 관련 질환 치료에 대한 수요가 증가하여 전반적인 의료비 지출이 증가하고 있습니다. 의료 투자의 증가는 약물, 진단 및 전문 치료에 대한 접근성을 개선함으로써 레이노병 치료를 향상시키는 동시에 연구 및 대중의 인식 개선 노력을 지원합니다. 2025년 4월, 미국 의학 협회(American Medical Association)의 보고서에 따르면, 2023년 미국의 의료비 지출은 7.5% 증가하여 4조 9천억 달러(1인당 14,570달러)에 달했으며, 이는 2022년의 4.6% 성장률보다 눈에 띄게 증가한 수치입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Raynaud's disease treatment involves both medical and lifestyle approaches designed to lessen the frequency and severity of blood vessel spasms in the fingers and toes caused by cold or emotional stress. This includes the use of medications such as calcium channel blockers to enhance blood circulation, as well as preventive actions like staying warm and managing stress effectively.

There are several main types of treatments available for Raynaud's disease, including medications, thermal therapies, surgical interventions, and alternative treatments. Medications typically consist of calcium channel blockers and vasodilators that enhance blood flow and alleviate Raynaud's symptoms. These drug types include calcium channel blockers, vasodilators, and antiplatelet agents, which may be administered via oral, topical, injectable, or intravenous routes. Treatment settings include hospitals, specialty clinics, homecare environments, and pharmacies.

The Raynaud's disease treatment market research report is one of a series of new reports from The Business Research Company that provides Raynaud's disease treatment market statistics, including Raynaud's disease treatment industry global market size, regional shares, competitors with a Raynaud's disease treatment market share, detailed Raynaud's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Raynaud's disease treatment industry. This Raynaud's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Raynaud's disease treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. This growth during the historic period is attributed to a rise in awareness of autoimmune diseases, enhanced diagnostic techniques, broader application of calcium channel blockers, a growing incidence of connective tissue disorders, and an aging population.

The Raynaud's disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Contributing factors to this projected growth include the increasing adoption of telehealth for vascular care, the development of personalized treatment approaches, ongoing studies into endothelial dysfunction, a higher prevalence driven by extreme weather conditions, and improvements in global healthcare systems. Notable trends anticipated during the forecast period include the use of AI for early detection and disease tracking, innovations in digital thermal diagnostic tools, progress in targeted biological therapies, emerging advancements in gene editing and cell therapy, as well as the wider implementation of digital health and telemedicine solutions.

The growing prevalence of autoimmune diseases is anticipated to drive the expansion of the Raynaud's disease treatment market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy tissues, leading to inflammation and tissue damage. This rise in autoimmune disorders is attributed to factors such as urbanized and sanitized living conditions that limit immune system training, as well as modern lifestyle elements like poor diet, stress, and environmental pollutants. Treatments for Raynaud's disease aid in managing autoimmune symptoms by improving symptom control, reducing tissue damage, and preventing complications caused by restricted blood flow. For example, in June 2024, a report from the Australian Institute of Health and Welfare revealed that in 2021-22 there were 10,000 hospitalizations for rheumatoid arthritis in Australia, a 25% increase from 8,000 the previous year, equivalent to 39 hospitalizations per 100,000 population. As a result, the increasing incidence of autoimmune conditions is fueling the growth of the Raynaud's disease treatment market.

Increasing healthcare expenditure is also expected to contribute to the growth of the Raynaud's disease treatment market. Healthcare expenditure refers to the total financial resources spent on medical services and health-related needs over a specific time period. As the global population ages, the demand for healthcare services, long-term care, and treatments for age-related conditions rises, leading to greater overall health spending. Increased healthcare investment enhances Raynaud's disease treatment by improving access to medications, diagnostics, and specialized care, while also supporting research and public awareness efforts. For instance, in April 2025, the American Medical Association reported that in 2023, U.S. health spending rose by 7.5% to reach $4.9 trillion, or $14,570 per person, a notable increase from the 4.6% growth recorded in 2022. This surge in spending supports the development and accessibility of treatments, thereby driving market growth.

Leading companies in the Raynaud's disease treatment market are concentrating on developing innovative therapeutic solutions, particularly oral calcium channel blockers that enhance blood flow by relaxing and dilating blood vessels, helping to reduce the frequency and severity of vasospastic attacks. Oral calcium channel blockers are medications taken by mouth that inhibit calcium entry into muscle cells in the heart and blood vessels, promoting vasodilation. For instance, in June 2023, Aisa Pharma Inc., a U.S.-based clinical-stage biopharmaceutical firm, launched the second part of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for treating Raynaud's phenomenon in individuals with systemic sclerosis (SSc). The trial follows encouraging results from the first phase, where Profervia demonstrated a more significant reduction in attack frequency and disease severity compared to other calcium channel blockers, along with a favorable safety and tolerability profile. The ongoing trial with a 20 mg dose seeks to meet the urgent need for effective Raynaud's treatments in SSc, which currently lacks approved therapies.

Major players in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., and Concert Pharmaceuticals Inc.

North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in raynauds disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the raynauds disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The raynauds disease treatment market consists of revenue earned by entities by providing services such as pharmacological management, thermal therapy services, surgical consultation, and behavioral therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The raynauds disease treatment market also includes sales of vasodilators, prostaglandins, hand warmers, thermal gloves, heated socks, and paraffin wax baths. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Raynauds Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on raynauds disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for raynauds disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The raynauds disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Raynauds Disease Treatment Market Characteristics

3. Raynauds Disease Treatment Market Trends And Strategies

4. Raynauds Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Raynauds Disease Treatment Growth Analysis And Strategic Analysis Framework

6. Raynauds Disease Treatment Market Segmentation

7. Raynauds Disease Treatment Market Regional And Country Analysis

8. Asia-Pacific Raynauds Disease Treatment Market

9. China Raynauds Disease Treatment Market

10. India Raynauds Disease Treatment Market

11. Japan Raynauds Disease Treatment Market

12. Australia Raynauds Disease Treatment Market

13. Indonesia Raynauds Disease Treatment Market

14. South Korea Raynauds Disease Treatment Market

15. Western Europe Raynauds Disease Treatment Market

16. UK Raynauds Disease Treatment Market

17. Germany Raynauds Disease Treatment Market

18. France Raynauds Disease Treatment Market

19. Italy Raynauds Disease Treatment Market

20. Spain Raynauds Disease Treatment Market

21. Eastern Europe Raynauds Disease Treatment Market

22. Russia Raynauds Disease Treatment Market

23. North America Raynauds Disease Treatment Market

24. USA Raynauds Disease Treatment Market

25. Canada Raynauds Disease Treatment Market

26. South America Raynauds Disease Treatment Market

27. Brazil Raynauds Disease Treatment Market

28. Middle East Raynauds Disease Treatment Market

29. Africa Raynauds Disease Treatment Market

30. Raynauds Disease Treatment Market Competitive Landscape And Company Profiles

31. Raynauds Disease Treatment Market Other Major And Innovative Companies

32. Global Raynauds Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Raynauds Disease Treatment Market

34. Recent Developments In The Raynauds Disease Treatment Market

35. Raynauds Disease Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기